Sorrento Therapeutics, Inc. (SRNE)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sorrento Therapeutics, Inc. (SRNE) trades at $0.00 with AI Score 50/100 (Hold). Sorrento Therapeutics, Inc. Market cap: $2.09M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Sorrento Therapeutics, Inc. (SRNE) Healthcare & Pipeline Overview
Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical firm leveraging its G-MAB antibody library and targeted delivery systems like CAR-T and Sofusa to develop therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases, operating in the competitive biotechnology sector with a focus on innovative drug delivery.
Investment Thesis
Sorrento Therapeutics presents a high-risk, high-reward investment profile characteristic of clinical-stage biotechnology companies. The company's diverse pipeline, spanning cancer, autoimmune, and neurodegenerative diseases, offers multiple potential value inflection points. Key value drivers include the successful advancement of its CAR-T therapy for multiple myeloma and the commercialization of resiniferatoxin for pain management. The Sofusa drug delivery technology could also unlock significant value by improving the efficacy and safety of biologics. However, the company's negative profit margin of -911.6% and reliance on future clinical trial successes pose significant risks. Upcoming clinical trial results and potential FDA approvals represent key catalysts. Investors should closely monitor clinical trial data, regulatory decisions, and the company's ability to secure additional funding to sustain operations.
Based on FMP financials and quantitative analysis
Key Highlights
- Sorrento Therapeutics operates in the high-growth biotechnology sector, focusing on innovative therapies for unmet medical needs.
- The company's proprietary G-MAB antibody library and targeted delivery modalities, such as CAR-T and Sofusa, differentiate it from competitors.
- Clinical programs include anti-CD38 CAR-T therapy for multiple myeloma, amyloidosis, and graft versus host disease.
- Developing resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin, for late-stage cancer and osteoarthritis knee pain treatment.
- The company has a negative profit margin of -911.6%, reflecting its focus on research and development and clinical trials.
Competitors & Peers
Strengths
- Proprietary G-MAB antibody library
- Targeted delivery modalities (CAR-T, Sofusa)
- Diverse pipeline of therapeutic candidates
- Strategic collaborations with leading institutions
Weaknesses
- Negative profit margin
- Reliance on clinical trial success
- Limited commercialized products
- High cash burn rate
Catalysts
- Upcoming: Clinical trial results for anti-CD38 CAR-T therapy in multiple myeloma.
- Upcoming: Regulatory submission for resiniferatoxin (RTX) in late-stage cancer pain.
- Ongoing: Expansion of Sofusa drug delivery technology through new partnerships.
- Ongoing: Phase III trial results for SEMDEXA in the treatment of sciatica.
- Ongoing: Potential for new strategic collaborations and acquisitions.
Risks
- Potential: Clinical trial failures for key pipeline candidates.
- Potential: Regulatory delays or rejections for drug approvals.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: High cash burn rate and need for additional funding.
- Ongoing: Patent expirations and intellectual property challenges.
Growth Opportunities
- Advancement of CAR-T Therapy: Sorrento's anti-CD38 CAR-T therapy for multiple myeloma represents a significant growth opportunity. The CAR-T therapy market is projected to reach $4.5 billion by 2028, driven by the increasing prevalence of hematological malignancies and the potential for CAR-T therapies to provide durable remissions. Successful clinical trials and regulatory approval could position Sorrento as a key player in this rapidly expanding market. Timeline: Ongoing clinical trials with potential for regulatory submission within the next 2-3 years.
- Commercialization of Resiniferatoxin (RTX): RTX, a non-opioid-based TRPV1 agonist neurotoxin, offers a promising alternative for pain management, particularly in late-stage cancer and osteoarthritis knee pain. The pain management market is estimated at $84 billion, with a growing demand for non-opioid alternatives due to the opioid crisis. Positive clinical trial results and subsequent commercialization could generate substantial revenue for Sorrento. Timeline: Late-stage clinical trials underway, with potential for market launch within 1-2 years.
- Expansion of Sofusa Drug Delivery Technology: Sorrento's Sofusa technology enables direct delivery of biologics into the lymphatic system, potentially enhancing drug efficacy and reducing systemic side effects. This technology can be applied to a wide range of therapeutic areas, including oncology, immunology, and infectious diseases. Partnering with other pharmaceutical companies to utilize Sofusa in their drug development programs could create a significant revenue stream for Sorrento. Timeline: Ongoing collaborations and potential for new partnerships within the next year.
- Development of SEMDEXA for Sciatica: SEMDEXA, an injectable viscous gel formulation for the treatment of sciatica, represents a significant market opportunity. Sciatica affects a large percentage of the population, and effective treatments are in high demand. Positive Phase III trial results and subsequent regulatory approval could lead to substantial market penetration. Timeline: Phase III trial underway, with potential for regulatory submission within 1-2 years.
- Strategic Collaborations and Partnerships: Sorrento's collaborations with SmartPharm Therapeutics Inc., Celularity, Inc., Mount Sinai Health System, and Mayo Clinic provide access to new technologies, expertise, and markets. These partnerships can accelerate the development and commercialization of Sorrento's pipeline products and expand its reach into new therapeutic areas. Actively pursuing and expanding strategic collaborations will be crucial for Sorrento's long-term growth. Timeline: Ongoing collaborations with potential for new partnerships within the next year.
Opportunities
- Advancement of CAR-T therapy for multiple myeloma
- Commercialization of resiniferatoxin for pain management
- Expansion of Sofusa drug delivery technology
- Strategic partnerships and acquisitions
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
Competitive Advantages
- Proprietary G-MAB antibody library provides a competitive advantage in antibody discovery and development.
- Targeted delivery modalities, such as CAR-T therapy and Sofusa, enhance drug efficacy and reduce side effects.
- Strong intellectual property portfolio protects Sorrento's technologies and drug candidates.
- Strategic collaborations with leading research institutions and pharmaceutical companies provide access to new technologies and markets.
About SRNE
Founded in 2006 and headquartered in San Diego, California, Sorrento Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for a range of diseases, including cancer, autoimmune disorders, inflammatory conditions, viral infections, and neurodegenerative diseases. The company operates through two segments: Sorrento Therapeutics and Scilex. Sorrento's core technology revolves around its proprietary G-MAB antibody library, which enables the identification and development of novel antibodies for therapeutic applications. The company employs various targeted delivery modalities, including chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, antibody-drug conjugates (ADCs), and bispecific antibody approaches. Sorrento's Sofusa drug delivery technology allows for the direct delivery of biologics into the lymphatic system, potentially enhancing drug efficacy and reducing systemic side effects. Sorrento's pipeline includes clinical programs such as anti-CD38 CAR-T therapy for multiple myeloma, amyloidosis, and graft versus host disease. The company is also developing resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin, for late-stage cancer and osteoarthritis knee pain, and ZTlido, a lidocaine delivery system for postherpetic neuralgia. Sorrento is also developing SEMDEXA for sciatica, SP-103 for chronic low back pain, and SP-104 for fibromyalgia. Sorrento has collaborations with SmartPharm Therapeutics Inc., Celularity, Inc., Mount Sinai Health System, and Mayo Clinic to develop therapies and conduct clinical trials.
What They Do
- Develop therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases.
- Utilize the proprietary G-MAB antibody library to discover and develop novel antibodies.
- Employ targeted delivery modalities, including CAR-T therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates.
- Develop Sofusa, a drug delivery technology for direct delivery of biologics into the lymphatic system.
- Develop resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for pain management.
- Develop ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia.
- Engage in clinical trials for various therapeutic candidates, including SEMDEXA for sciatica, SP-103 for chronic low back pain, and SP-104 for fibromyalgia.
- Collaborate with other companies and institutions to develop and commercialize therapies.
Business Model
- Develop and commercialize pharmaceutical products.
- Generate revenue through product sales and licensing agreements.
- Collaborate with other companies and institutions to develop and commercialize therapies.
- Out-license technologies and drug candidates to generate revenue.
Industry Context
Sorrento Therapeutics operates within the highly competitive biotechnology industry, characterized by rapid innovation, intense competition, and significant regulatory hurdles. The industry is driven by the increasing demand for novel therapies to address unmet medical needs in areas such as cancer, autoimmune diseases, and neurodegenerative disorders. Companies like Sorrento are focusing on developing innovative drug delivery systems and targeted therapies to improve treatment outcomes and reduce side effects. The competitive landscape includes established pharmaceutical giants and smaller, specialized biotechnology firms. The biotechnology industry is experiencing substantial growth, driven by advances in genomics, proteomics, and personalized medicine.
Key Customers
- Patients suffering from cancer, autoimmune diseases, inflammatory conditions, viral infections, and neurodegenerative diseases.
- Hospitals and clinics that administer Sorrento's therapies.
- Pharmaceutical companies that license Sorrento's technologies and drug candidates.
- Research institutions that collaborate with Sorrento on drug development.
Financials
Chart & Info
Sorrento Therapeutics, Inc. (SRNE) stock price: $0.00 (-0.00, -11.11%)
Latest News
No recent news available for SRNE.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SRNE.
Price Targets
Wall Street price target analysis for SRNE.
MoonshotScore
What does this score mean?
The MoonshotScore rates SRNE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Henry H. Ji
CEO
Henry H. Ji serves as the CEO of Sorrento Therapeutics, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. Prior to joining Sorrento, he held various leadership positions in research and development, business development, and corporate strategy. He has a strong track record of driving innovation and building successful biotechnology companies. His expertise spans drug discovery, clinical development, and commercialization.
Track Record: Under Henry Ji's leadership, Sorrento Therapeutics has focused on expanding its pipeline of therapeutic candidates and advancing its proprietary technologies. Key achievements include the development of the G-MAB antibody library, the advancement of CAR-T therapy programs, and the expansion of strategic collaborations. He has also overseen the acquisition of complementary technologies and companies to strengthen Sorrento's market position.
SRNE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sorrento Therapeutics may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, be undergoing restructuring, or have regulatory issues. Investing in OTC Other stocks carries significantly higher risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of stringent listing requirements and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Lack of regulatory oversight
- Low trading volume and liquidity
- High price volatility
- Potential for fraud or manipulation
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor the company's news and press releases for any red flags.
- Consult with a qualified financial advisor before investing.
- Established research and development programs
- Strategic collaborations with reputable institutions
- Patents and intellectual property protection
- Experienced management team
- Focus on addressing unmet medical needs
Common Questions About SRNE
What does Sorrento Therapeutics, Inc. do?
Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for a range of diseases, including cancer, autoimmune disorders, inflammatory conditions, viral infections, and neurodegenerative diseases. The company leverages its proprietary G-MAB antibody library and targeted delivery modalities, such as CAR-T therapy and Sofusa, to discover and develop novel antibodies and therapeutic candidates. Sorrento's pipeline includes clinical programs in various stages of development, targeting unmet medical needs in oncology, pain management, and other therapeutic areas. The company also collaborates with other companies and institutions to develop and commercialize its therapies.
What do analysts say about SRNE stock?
Analyst coverage of Sorrento Therapeutics, Inc. is varied, reflecting the inherent risks and potential rewards associated with clinical-stage biotechnology companies. Some analysts highlight the company's diverse pipeline and innovative technologies, while others express concerns about its financial performance and reliance on future clinical trial successes. Key valuation metrics include potential peak sales for its lead drug candidates and the value of its proprietary technologies. Growth considerations include the successful advancement of its clinical programs and the ability to secure additional funding. Analyst ratings and price targets should be viewed in the context of the company's risk profile and the inherent uncertainty of drug development.
What are the main risks for SRNE?
Sorrento Therapeutics, Inc. faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the company's pipeline relies on the successful development of its therapeutic candidates. Regulatory hurdles and potential delays in drug approvals could also impact the company's timeline and financial performance. Competition from established pharmaceutical companies and other biotechnology firms poses a threat to Sorrento's market share. The company's high cash burn rate and need for additional funding could dilute existing shareholders. Patent expirations and intellectual property challenges could also impact the company's long-term prospects. Investors should carefully consider these risks before investing in Sorrento Therapeutics, Inc.
What are the key factors to evaluate for SRNE?
Sorrento Therapeutics, Inc. (SRNE) currently holds an AI score of 50/100, indicating moderate score. Key strength: Proprietary G-MAB antibody library. Primary risk to monitor: Potential: Clinical trial failures for key pipeline candidates.. This is not financial advice.
How frequently does SRNE data refresh on this page?
SRNE prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SRNE's recent stock price performance?
Recent price movement in Sorrento Therapeutics, Inc. (SRNE) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary G-MAB antibody library. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SRNE overvalued or undervalued right now?
Determining whether Sorrento Therapeutics, Inc. (SRNE) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SRNE?
Before investing in Sorrento Therapeutics, Inc. (SRNE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-15.
- Financial data may be outdated due to the company's OTC status and potential lack of recent filings.
- Clinical trial outcomes are inherently uncertain and subject to change.